{"id":"standard-dose-intravenous-tenecteplase","safety":{"commonSideEffects":[{"rate":"null","effect":"Hemorrhage"},{"rate":"null","effect":"Allergic reactions"}]},"_chembl":{"chemblId":"CHEMBL2108791","moleculeType":"Enzyme"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This process is crucial for the treatment of acute ischemic stroke, as it helps to restore blood flow to the affected area of the brain. Tenecteplase is a recombinant form of tPA, which has a higher specificity and lower risk of bleeding compared to its natural counterpart.","oneSentence":"Tenecteplase is a tissue plasminogen activator that works by catalyzing the conversion of plasminogen to plasmin, resulting in the breakdown of blood clots.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:36:05.868Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute ischemic stroke"}]},"trialDetails":[{"nctId":"NCT07294209","phase":"PHASE4","title":"Low-Dose Tenecteplase for Acute Ischemic Stroke Treatment in Aging Patients","status":"RECRUITING","sponsor":"Southwest Hospital, China","startDate":"2025-12-19","conditions":"Acute Ischemic Stroke Patients","enrollment":798},{"nctId":"NCT07203625","phase":"PHASE4","title":"Tenecteplase Before Interhospital Transfer in Acute Basilar Artery Occlusion at 4.5 to 24 Hours","status":"RECRUITING","sponsor":"Xuanwu Hospital, Beijing","startDate":"2026-01-20","conditions":"Acute Ischemic Stroke, Basilar Artery Occlusion","enrollment":316},{"nctId":"NCT07253181","phase":"PHASE3","title":"Tenecteplase Before Interhospital Transfer for EVT in Acute Anterior Circulation LVO at 4.5-24 Hours","status":"RECRUITING","sponsor":"Xuanwu Hospital, Beijing","startDate":"2026-01-06","conditions":"Acute Ischemic Stroke, Large Vessel Occlusion, Transportation of Patients","enrollment":572},{"nctId":"NCT07476898","phase":"PHASE3","title":"Precision Reperfusion Therapy for Disabling Minor Stroke With Large Vessel Occlusion Beyond Time Window","status":"NOT_YET_RECRUITING","sponsor":"First Hospital of China Medical University","startDate":"2026-03-01","conditions":"Stroke","enrollment":864},{"nctId":"NCT07475949","phase":"PHASE3","title":"Unknown Time of Onset Stroke RePerfusIon Without Advanced Imaging","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Guangxi Medical University","startDate":"2026-04","conditions":"Acute Ischemic Stroke, Tenecteplase","enrollment":352},{"nctId":"NCT07475936","phase":"","title":"Intravenous Tenecteplase in Very Old Patients With Acute Ischemic Stroke","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Guangxi Medical University","startDate":"2026-04","conditions":"Acute Ischemic Stroke, Tenecteplase","enrollment":392},{"nctId":"NCT07047014","phase":"PHASE3","title":"Advancing Reperfusion Therapy for Ischemic Stroke (ARTS): Tenecteplase in Medium Vessel Occlusion (MeVO) for Acute Ischemic Stroke","status":"RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2025-07-30","conditions":"Stroke, Ischemic, Medium Vessel Occlusions","enrollment":596},{"nctId":"NCT06954155","phase":"PHASE3","title":"Tenecteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-BEYOND","status":"RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2025-05-30","conditions":"Stroke","enrollment":330},{"nctId":"NCT06320431","phase":"PHASE3","title":"ACT-GLOBAL THROMBOLYSIS (ACT-WHEN-001) Domain Within the ACT-GLOBAL Adaptive Platform Trial-NCT06352632","status":"RECRUITING","sponsor":"University of Calgary","startDate":"2024-09-26","conditions":"Acute Ischemic Stroke AIS, Stroke Acute, Stroke, Acute, Stroke Ischemic","enrollment":4000},{"nctId":"NCT07168278","phase":"PHASE3","title":"Tenecteplase vs Medical Management in 4.5-24h LVO no Access to EVT","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of University of Science and Technology of China","startDate":"2025-11-01","conditions":"Acute Ischemic Stroke, Large Vessel Occlusion, Tenecteplase","enrollment":794},{"nctId":"NCT07073469","phase":"PHASE3","title":"Tenecteplase in ReperfUsion Therapy for Posterior Circulation Stroke With Extended Time Window: the TRUST Trial","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-09-01","conditions":"Stroke Ischemic","enrollment":330},{"nctId":"NCT07094763","phase":"NA","title":"Efficacy and Safety of Tenecteplase Intravenous Thrombolysis in Acute Posterior Circulation Ischemic Stroke Within 4.5-24 Hours After Onset","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of University of Science and Technology of China","startDate":"2025-08-05","conditions":"Acute Ischemic Stroke","enrollment":406},{"nctId":"NCT06115070","phase":"PHASE4","title":"Intravenous Thrombolytic Therapy for Acute Ischemic Stroke Patients with Low NIHSS and Non-disabling Deficits","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-03-01","conditions":"Thrombosis, Acute Ischemic Stroke (AIS)","enrollment":390},{"nctId":"NCT06841965","phase":"PHASE3","title":"Intravenous Thrombolysis in Acute Ischemic Stroke with Active Cancer","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-03-01","conditions":"Stroke, Acute Ischemic Stroke","enrollment":280},{"nctId":"NCT06749834","phase":"PHASE3","title":"Intravenous Thrombolysis and NOAC","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-01-27","conditions":"Acute Ischemic Stroke","enrollment":280},{"nctId":"NCT06841978","phase":"PHASE3","title":"Intravenous Thrombosis and Patients with Prior Ischemic Stroke Within 3 Months","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-03-01","conditions":"Stroke, Acute Ischemic Stroke","enrollment":306},{"nctId":"NCT02398656","phase":"PHASE3","title":"A Randomized Controlled Trial of TNK-tPA Versus Standard of Care for Minor Ischemic Stroke With Proven Occlusion","status":"COMPLETED","sponsor":"University of Calgary","startDate":"2015-04-01","conditions":"Stroke, Acute","enrollment":1274},{"nctId":"NCT04454788","phase":"PHASE3","title":"Extending the Time Window for Tenecteplase by Effective Reperfusion in Patients with Large Vessel Occlusion","status":"TERMINATED","sponsor":"University of Melbourne","startDate":"2020-08-01","conditions":"Ischemic Stroke","enrollment":242},{"nctId":"NCT06352632","phase":"PHASE3","title":"ACT-GLOBAL Adaptive Platform Trial for Stroke","status":"RECRUITING","sponsor":"The George Institute","startDate":"2024-09-26","conditions":"Stroke","enrollment":20000},{"nctId":"NCT06559436","phase":"NA","title":"Extending the Time Window for Intravenous Tenecteplase in Patients With Distal Medium Vessel Occlusions Stroke","status":"RECRUITING","sponsor":"The First Affiliated Hospital of University of Science and Technology of China","startDate":"2024-10-02","conditions":"Acute Ischemic Stroke","enrollment":560},{"nctId":"NCT02814409","phase":"PHASE3","title":"Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis","status":"COMPLETED","sponsor":"NHS Greater Glasgow and Clyde","startDate":"2016-12-15","conditions":"Ischemic Stroke","enrollment":1858},{"nctId":"NCT05141305","phase":"PHASE3","title":"Teneteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-III","status":"COMPLETED","sponsor":"Beijing Tiantan Hospital","startDate":"2022-01-19","conditions":"Ischemic Stroke, Acute","enrollment":516},{"nctId":"NCT05105633","phase":"PHASE2, PHASE3","title":"Extending the Time Window for Tenecteplase by Recanalization of Basilar Artery Occlusion in Posterior Circulation Stroke","status":"RECRUITING","sponsor":"University of Melbourne","startDate":"2021-11-29","conditions":"Basilar Artery Occlusion","enrollment":688},{"nctId":"NCT03889249","phase":"PHASE3","title":"Alteplase Compared to Tenecteplase in Patients With Acute Ischemic Stroke","status":"COMPLETED","sponsor":"University of Calgary","startDate":"2019-12-10","conditions":"Stroke, Acute, Thromboses, Intracranial","enrollment":1600},{"nctId":"NCT05745259","phase":"PHASE3","title":"Thrombolysis Treated With TNK-tPA in Acute Ischemic Stroke Patients （3T Stroke-Ⅲ）","status":"UNKNOWN","sponsor":"Beijing Tiantan Hospital","startDate":"2022-10-26","conditions":"Acute Ischemic Stroke","enrollment":1630},{"nctId":"NCT05626972","phase":"PHASE3","title":"Tenecteplase Compared to Alteplase for Patients With Large Vesel Oclusion Suspicion Before Thrombectomy","status":"UNKNOWN","sponsor":"Hospital Universitari Vall d'Hebron Research Institute","startDate":"2022-05-27","conditions":"Acute Ischemic Stroke","enrollment":500},{"nctId":"NCT05281549","phase":"PHASE2","title":"Thrombolysis Treated With TNK-tPA in Acute Ischemic Stroke Patients （3T Stroke-II）","status":"UNKNOWN","sponsor":"Beijing Tiantan Hospital","startDate":"2021-05-02","conditions":"Acute Ischemic Stroke","enrollment":225},{"nctId":"NCT04071613","phase":"PHASE2","title":"Tenecteplase Versus Alteplase for Stroke Thrombolysis Evaluation Trial in the Ambulance","status":"COMPLETED","sponsor":"Melbourne Health","startDate":"2019-06-20","conditions":"Stroke, Acute, Stroke Ischemic","enrollment":104},{"nctId":"NCT04558125","phase":"PHASE4","title":"Low-Dose Tenecteplase in Covid-19 Diagnosed With Pulmonary Embolism","status":"TERMINATED","sponsor":"Cedars-Sinai Medical Center","startDate":"2020-09-08","conditions":"Pulmonary Embolism, COVID","enrollment":2},{"nctId":"NCT03181360","phase":"PHASE3","title":"Tenecteplase in Wake-up Ischaemic Stroke Trial","status":"UNKNOWN","sponsor":"University Hospital of North Norway","startDate":"2017-06-12","conditions":"Ischemic Stroke, Stroke, Acute","enrollment":600},{"nctId":"NCT02338466","phase":"PHASE2","title":"Superiority of Rt-PA + Tenecteplase in Comparison With Rt-PA Only in Proximal Middle Cerebral Artery Occlusion","status":"WITHDRAWN","sponsor":"University Hospital Center of Martinique","startDate":"2016-07","conditions":"Nervous System Disorders, Cerebral Artery","enrollment":""},{"nctId":"NCT02388061","phase":"PHASE2","title":"Tenecteplase Versus Alteplase Before Endovascular Therapy for Ischemic Stroke","status":"COMPLETED","sponsor":"Neuroscience Trials Australia","startDate":"2015-03-23","conditions":"Ischemic Stroke","enrollment":202}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Standard-dose intravenous tenecteplase","genericName":"Standard-dose intravenous tenecteplase","companyName":"The George Institute","companyId":"the-george-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tenecteplase is a tissue plasminogen activator that works by catalyzing the conversion of plasminogen to plasmin, resulting in the breakdown of blood clots. Used for Acute ischemic stroke.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}